Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05876754	Phase III	Ivosidenib	An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)	Recruiting	SWE \| ROU \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	2
NCT06127407	Phase III	Ivosidenib	Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)	Recruiting	USA \| CAN \| BRA \| AUS	1
NCT04164901	Phase III	Vorasidenib	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	Active, not recruiting	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN	1
NCT04056910	Phase II	Ivosidenib + Nivolumab	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Completed	USA	0
NCT03953898	Phase II	Olaparib	Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	Active, not recruiting	USA	0
NCT05303519	Phase II	DS-1001b	Safusidenib Phase 2 Study in IDH1 Mutant Glioma	Recruiting	USA	0
NCT05921760	Phase Ib/II	Ipilimumab + Ivosidenib + Nivolumab	Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma	Active, not recruiting	USA \| GBR	0
NCT04088188	Phase I	Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib	Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma	Terminated	USA	0
NCT06161974	Phase II	Olutasidenib + Temozolomide	Study of Olutasidenib and Temozolomide in HGG	Not yet recruiting	USA \| NLD \| GBR \| DEU \| CAN \| AUS	0
NCT03914742	Phase Ib/II	Pamiparib + Temozolomide	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations	Completed	USA	0
NCT04779151	Phase II	Dostarlimab-gxly + Niraparib	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)	Suspended	FRA	0
NCT04493164	Phase II	CPX-351 + Ivosidenib Ivosidenib	CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT05406700	Phase I	Niraparib	Niraparib In Recurrent IDH 1/2 Gliomas	Recruiting	USA	0
NCT05743595	Phase I	Personalized cancer vaccine + Retifanlimab	Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Recruiting	USA	0
NCT03207347	Phase II	Niraparib	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Completed	USA	0
NCT02525692	Phase II	ONC201	Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma	Active, not recruiting	USA	0
NCT04278781	Phase II	Ivosidenib	AG-120 in People With IDH1 Mutant Chondrosarcoma	Active, not recruiting	USA	0
NCT02481154	Phase I	Vorasidenib	Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation	Completed	USA	0
NCT02073994	Phase I	Ivosidenib	Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation	Completed	USA \| FRA	0
NCT04729959	Phase II	Atezolizumab + Tocilizumab	Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma	Recruiting	USA	0
NCT04955938	Phase I	Enasidenib + Fedratinib Fedratinib + Ivosidenib	A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Withdrawn	USA	0
NCT03749187	Phase I	Pamiparib + Temozolomide	BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)	Recruiting	USA	0
NCT06291987	Phase I	Ivosidenib + Ruxolitinib	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)	Recruiting	USA	0
NCT06636162	Phase I	DSP-0390	Window of Opportunity Study of DSP-0390 in Gliomas	Not yet recruiting	USA	0
NCT03212274	Phase II	Olaparib	Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	Active, not recruiting	USA	0
NCT06455605	Phase Ib/II	2141 V-11 + D2C7-IT	D2C7-IT + 2141-V11 Combination Post-resection in rGBM	Not yet recruiting	USA	0
NCT05188508	Phase II	Olaparib + Pembrolizumab + Temozolomide	Pembrolizumab, Olaparib, and Temozolomide for People With Glioma	Recruiting	USA	0
NCT03430791	Phase II	Ipilimumab + Nivolumab Nivolumab	Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma	Terminated	USA	0
NCT05218408	Phase Ib/II	Cyclophosphamide + Fludarabine CYNK-001	CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02)	Withdrawn		0
NCT05099003	Phase Ib/II	Selinexor	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	Recruiting	USA \| NZL \| CAN \| AUS	0
NCT05538572	Phase I	PRT3645	A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors	Completed	USA	1
NCT03127735	Phase I	BAY1436032	BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)	Completed	USA \| DEU	0
NCT02981940	Phase II	Abemaciclib	A Study of Abemaciclib in Recurrent Glioblastoma	Active, not recruiting	USA	0
NCT02492737	Phase I	Vorasidenib	Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation	Completed	USA \| FRA	0
NCT05432375	Phase I	Tinostamustine	Study of Tinostamustine for Adjuvant Treatment of Glioblastoma	Active, not recruiting	ESP \| CHE	0
NCT04945148	Phase II	Metformin + Temozolomide	Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM)	Recruiting	ITA \| FRA	0
NCT05588141	Phase Ib/II	Zotiraciclib	Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations	Recruiting	USA	0
NCT03047993	Phase Ib/II	Azacitidine + Telaglenastat	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	Completed	USA	0
NCT02677922	Phase Ib/II	Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib	A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy	Active, not recruiting	USA \| SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	2
NCT04195555	Phase II	Ivosidenib	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA \| AUS	1
NCT06668584	Phase Ib/II	Olutasidenib	A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients with IDH1-mutated Myeloid Malignancies	Not yet recruiting	USA	0
NCT05376800	Phase I	BI 907828	A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma	Recruiting	USA \| ESP \| BEL	0
NCT05222802	Phase I	ERAS-801	A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)	Active, not recruiting	USA	0
NCT03158389	Phase Ib/II	Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101	NCT Neuro Master Match - N²M² (NOA-20) (N²M²)	Completed	DEU	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT05345002	Phase II	Retifanlimab + Tretinoin	All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma	Recruiting	USA	0
NCT03718767	Phase II	Nivolumab	Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype	Recruiting	USA	0
NCT06258018	Phase Ib/II	Niraparib + Temozolomide	Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001)	Not yet recruiting	ITA	0
NCT06478212	Phase Ib/II	Temozolomide + Vorasidenib	Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma	Not yet recruiting	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| AUT	2
NCT05463848	Phase II	Olaparib + Pembrolizumab + Temozolomide Pembrolizumab	Surgical Pembro +/- Olaparib w TMZ for rGBM	Recruiting	USA	0
NCT04762602	Phase I	HMPL-306	A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations	Active, not recruiting	USA \| ESP	0
NCT05417594	Phase Ib/II	AZD9574 AZD9574 + Temozolomide	Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)	Recruiting	USA \| SWE \| GBR \| ESP \| DEU \| AUS	1
NCT05326464	Phase III	Tofacitinib	Tofacitinib in Recurrent GBM Patients	Recruiting	USA	0
NCT04908176	Phase I	Avapritinib + Midazolam	A Drug-drug Interaction Study of Avapritinib and Midazolam	Active, not recruiting	USA	0
NCT04774393	Phase Ib/II	Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax	Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	USA	0
NCT04015700	Phase I	GNOS-PV01 + INO-9012	Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Active, not recruiting	USA	0
NCT03922555	Phase I	Decitabine and Cedazuridine	ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas	Recruiting	USA	0
NCT06095375	Phase I	Regorafenib + Temozolomide	Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)	Recruiting	ITA	0
NCT06297512	Phase II	Doxorubicin + Temozolomide	Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).	Recruiting	ITA	0
NCT06543381	Phase I	Olutasidenib	Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant	Recruiting	USA	0
NCT05879120	Phase II	Pembrolizumab	Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma	Withdrawn	USA	0
NCT03878095	Phase II	Ceralasertib + Olaparib	Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	Active, not recruiting	USA	0
NCT05401097	Phase II	Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax	IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)	Recruiting	USA	0
NCT04118036	Phase II	Abemaciclib + Pembrolizumab	Abemaciclib + Pembrolizumab In Glioblastoma	Withdrawn	USA	0
NCT05474378	Phase I	Retroviral vector transduced B7-H3 CAR T cells	B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme	Recruiting	USA	0
NCT02071862	Phase I	Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Completed	USA	0
NCT05766514	Phase II	Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax	Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction	Not yet recruiting	USA	0
NCT05432804	Phase Ib/II	Selinexor + Temozolomide Temozolomide	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	Recruiting	USA	0
NCT03173248	Phase III	Azacitidine Azacitidine + Ivosidenib	Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUT \| AUS	6
NCT05465954	Phase II	NT-I7 + Pembrolizumab	Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma	Recruiting	USA	0
NCT05183204	Phase II	GDC-0084 + Metformin	Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma	Recruiting	USA	0
NCT05627323	Phase I	CHM-1101	CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma	Active, not recruiting	USA	0
NCT04396860	Phase II	Temozolomide Ipilimumab + Nivolumab	Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma	Active, not recruiting	USA	0
NCT03701295	Phase Ib/II	Azacitidine + Pinometostat	Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement	Completed	USA	0
NCT06413706	Phase II	Abemaciclib + Temozolomide Temozolomide	A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Not yet recruiting	USA \| ROU \| ITA \| FRA \| ESP \| DNK \| BEL	1
NCT06566742	Phase II	Olutasidenib	A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.	Not yet recruiting	USA	0
NCT03557359	Phase II	Nivolumab	Nivolumab for Recurrent or Progressive IDH Mutant Gliomas	Active, not recruiting	USA	0
NCT04606316	Phase I	Nivolumab Ipilimumab + Nivolumab	Surgical Nivolumab And Ipilimumab For Recurrent GBM	Active, not recruiting	USA	0
NCT06597734	Phase II	Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib	A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm	Not yet recruiting	USA	0
NCT04559230	Phase II	Sacituzumab govitecan-hziy	Sacituzumab Govitecan in Recurrent Glioblastoma	Recruiting	USA	0
NCT04988555	Phase Ib/II	DSP-5336	A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation	Recruiting	USA \| ITA \| FRA \| ESP \| CAN \| BEL	4
NCT02968940	Phase II	Avelumab	Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma	Completed	USA	0
NCT05052957	Phase II	Carmustine + Filgrastim + O6-benzylguanine + Temozolomide	hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM)	Recruiting	USA	0
NCT02858895	Phase II	MDNA55	Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma	Completed	USA	0
NCT02428855	Phase II	Dasatinib	Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma	Completed	USA	0
NCT04764474	Phase I	HMPL-306	A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH	Recruiting	USA \| ESP	0
NCT03503409	Phase II	Ivosidenib	IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	Active, not recruiting	ITA \| FRA	0
NCT04629209	Phase II	ONC201	A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma	Withdrawn	USA	0
NCT04576117	Phase III	Selumetinib Selumetinib + Vinblastine	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	Recruiting	USA \| CAN	0
NCT04555577	Phase I	Peposertib Temozolomide	Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma	Recruiting	USA	0
NCT02632708	Phase I	Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib	Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation	Active, not recruiting	USA \| NLD \| DEU	0
NCT05756777	Phase I	Gilteritinib + Ivosidenib Enasidenib + Gilteritinib	A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)	Recruiting	USA	0
NCT05180825	Phase II	Vinblastine Trametinib	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC)	Recruiting	FRA	0
NCT03991832	Phase II	Durvalumab + Olaparib	Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID)	Recruiting	CAN	0
NCT03220646	Phase II	Abemaciclib	Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors	Active, not recruiting	USA	0
NCT02989857	Phase III	Ivosidenib	Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)	Completed	USA \| ITA \| GBR \| FRA \| ESP	1
NCT05283109	Phase I	P30-EPS + Poly ICLC	ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I)	Recruiting	USA	0
NCT03139916	Phase II	Bavituximab + Temozolomide	Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma	Completed	USA	0
NCT05484622	Phase I	Vorasidenib Pembrolizumab + Vorasidenib	Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma	Recruiting	USA	0
NCT03224104	Phase I	Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib	Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM)	Completed	NLD \| FRA \| DEU \| CHE \| AUT	0
NCT03343197	Phase I	Ivosidenib Vorasidenib	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	Active, not recruiting	USA	0
NCT02977780	Phase II	CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide	INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)	Recruiting	USA	0
NCT02193347	Phase I	Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide	IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)	Completed	USA	0
NCT05609994	Phase I	PEPIDH1M vaccine + Vorasidenib	ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy)	Not yet recruiting	USA	0
NCT03970447	Phase II	Lomustine Regorafenib Temozolomide	A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)	Recruiting	USA \| FRA \| DEU \| CHE \| CAN \| AUS	0
NCT06325683	Phase II	Nivolumab + Relatlimab Lomustine	Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma	Recruiting	USA	0
NCT03893903	Phase I	Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine	AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC)	Active, not recruiting	DEU	0
NCT05859334	Phase II	Erdafitinib	Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment	Recruiting	USA \| CAN	0
NCT04573192	Phase Ib/II	Lomustine + Onfekafusp alfa Lomustine	A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR)	Recruiting	ITA \| FRA \| DEU \| CHE	0
NCT03018288	Phase II	Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen	Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)	Terminated	USA	0
NCT03631836	Phase I	Andecaliximab + Bevacizumab	Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01)	Unknown status	FRA	0
NCT03896568	Phase I	DNX-2401	MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma	Recruiting	USA	0
NCT03743662	Phase II	Nivolumab Bevacizumab	Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma	Active, not recruiting	USA	0
NCT04225039	Phase II	INCAGN01876 + Retifanlimab	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	Active, not recruiting	USA	0
NCT04197934	Phase I	WSD0922	WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases	Recruiting	USA	0
NCT01891747	Phase I	Bevacizumab + Temozolomide	A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma	Completed	USA	0
NCT03696355	Phase I	GDC-0084	Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas	Completed	USA	0
NCT03452930	Phase I	Tinostamustine	Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma	Completed	USA	0
NCT04910022	Phase Ib/II	NMS-03305293 + Temozolomide Lomustine	Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma	Recruiting	USA \| NLD \| ITA \| CHE	0
NCT04550494	Phase II	Talazoparib	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Recruiting	USA	0
NCT03471260	Phase Ib/II	Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax	Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies	Recruiting	USA	0
NCT03684811	Phase Ib/II	Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib	A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Completed	USA \| GBR \| FRA \| ESP \| AUS	1
NCT04013880	Phase Ib/II	Decitabine and Cedazuridine + Olutasidenib	ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Withdrawn		0
NCT03839771	Phase III	Ivosidenib Enasidenib	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)	Active, not recruiting	SWE \| NOR \| NLD \| LUX \| LTU \| IRL \| FRA \| FIN \| EST \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS	0
NCT04655391	Phase I	Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib	Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation	Withdrawn	USA	0
NCT02719574	Phase I	Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib	Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT03564821	Phase I	Ivosidenib	IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation	Completed	USA	0
NCT02977689	Phase II	IDH305	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma	Withdrawn	USA	0
NCT02381886	Phase I	IDH305	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	Active, not recruiting	USA \| NLD \| ESP \| DEU \| CAN \| BEL \| AUS	1
NCT04603001	Phase I	LY3410738	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	Active, not recruiting	USA \| ISR \| FRA \| FIN \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT04250051	Phase I	Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	USA	0
NCT02746081	Phase I	BAY1436032	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	Active, not recruiting	USA \| DNK \| DEU	1
NCT03528642	Phase I	Radiotherapy + Telaglenastat + Temozolomide	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	Active, not recruiting	USA	0
NCT04521686	Phase I	LY3410738	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Active, not recruiting	USA \| FRA \| ESP \| AUS	5
NCT02074839	Phase I	Ivosidenib	Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation	Recruiting	USA \| FRA	0

Gene Detail

Contact

Filtering

Sorting